Sage Therapeutics (Sage Therapeutics) EV-to-Revenue : 0.03 (As of May. 12, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sage Therapeutics's enterprise value is $2.46 Mil. Sage Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $91.06 Mil. Therefore, Sage Therapeutics's EV-to-Revenue for today is 0.03.

The historical rank and industry rank for Sage Therapeutics's EV-to-Revenue or its related term are showing as below:

SAGE' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.02 Med: 74.98 Max: 5297.16
Current: 0.03

During the past 12 years, the highest EV-to-Revenue of Sage Therapeutics was 5297.16. The lowest was 0.02. And the median was 74.98.

SAGE's EV-to-Revenue is ranked better than
91.15% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs SAGE: 0.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Sage Therapeutics's stock price is $11.90. Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.52. Therefore, Sage Therapeutics's PS Ratio for today is 7.84.

Sage Therapeutics EV-to-Revenue Historical Data

The historical data trend for Sage Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics EV-to-Revenue Chart

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

403.86

2.67

124.18

131.32

6.40

Sage Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															147.73	175.25	32.17	6.40	4.55

Competitive Comparison of Sage Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Sage Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sage Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's EV-to-Revenue falls into.

Sage Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sage Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2.459	/	91.064
	=	0.03

Sage Therapeutics's current Enterprise Value is $2.46 Mil.
Sage Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $91.06 Mil.

Sage Therapeutics (NAS:SAGE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sage Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	11.90	/	1.517
	=	7.84

Sage Therapeutics's share price for today is $11.90.
Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.52.

Sage Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (Sage Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SG7:Germany SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Executives

Elizabeth Barrett	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas	director, officer: See Remarks	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault	officer: Chief Medical Officer	C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi	officer: Chief Commercial Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates	director	88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud	officer: Chief Scientific Officer	215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan	officer: Chief Business Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook	officer: General Counsel	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi	officer: See Remarks	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035